Citations

Clear

5400 citation(s) found for "Louis, E".

A translational platform for brain-computer interfaces and adaptive neuromodulation: Technical characterization, long-term validation, and implementation of the CorTec brain interchange-BCI2000 ecosystem
Lampert, Frederik , Baker, Matthew R , Engelhardt, William , Gkogkidis, C Alexis , Ayyoubi, Amir Hossein , Fazli Besheli, Behrang , Boom, Max van den , Kellar, Douglas J , Kim, Inyong , Staff, Nathan P , Schalk, Gerwin , Ince, Nuri Firat

Mayo Clinic

Journal of Neural Engineering | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1088/1741-2552/aec198 | PMID 43019594 Get It

Abstract Objective: Adaptive neuromodulation systems and implantable brain-computer interfaces (BCIs) are promising therapies for neurological and psychiatric disorders. However, their broader translation into research and clinical practice remains limited by technological complexity, restricted access to implantable research platforms, and the lack of standardized, reproducible experimental workflows. We therefore aimed to develop and validate an open, general-purpose translational ecosystem that enables rapid development, evaluation, and dissemination of novel neuromodulation and implantable BCI paradigms.
Approach: The CorTec Brain Interchange (BIC) implantable neural sensing and stimulation device was integrated with the open-source BCI2000 platform to create a modular, extensible neuromodulation ecosystem. We established a standardized battery of quantitative assessments to characterize implantable neuromodulation systems to comprehensively evaluate the CorTec BIC device through benchtop characterization, long-term preclinical in vivo validation, and a human feasibility demonstration using the benchtop BIC system connected to externalized leads.
Results: Comprehensive benchtop characterization of the BIC device independently validated previously reported performance while extending its evaluation through quantification of recording noise, acquisition and stimulation latencies, and validation of impedance measurements. Long-term in vivo validation in five canines, with the longest implantation exceeding three years, demonstrated stable chronic recordings while also capturing progressive deterioration of individual channels through longitudinal changes in signal quality and impedance. The ecosystem enabled active functional decoding more than two years after implantation, closed-loop stimulation using arbitrary spectral biomarkers, capturing brain stimulation evoked potentials, detection of epilepsy-associated biomarkers and observational assessment of their response to stimulation. In addition, we translated an established one-dimensional BCI cursor-control paradigm to the BIC benchtop system, demonstrating ecosystem portability and feasibility with a human participant. Finally, we share surgical protocols, imaging and analysis pipelines, datasets, and software to facilitate reproducible neuromodulation research.
Significance: We present a versatile, open-source translational ecosystem that supports a wide range of neuromodulation and implantable BCI applications with minimal modification. By combining comprehensive hardware characterization with standardized software tools and experimental workflows, this work provides a practical reference for researchers adopting the BIC platform while establishing a broadly applicable framework for systematic characterization of implantable neuromodulation systems. The ecosystem lowers technical barriers to implantable neurotechnology research, promotes reproducibility, and provides a foundation for accelerating the development and clinical translation of next-generation adaptive neuromodulation and implantable BCI therapies for patients with neurological and psychiatric disorders.
Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study
Sen, Mitali , Ruan, Gordon J , Reynolds, Samuel , Ali, Haadi , Morlote, Diana M. , Koster, Matthew J , Abeykoon, Jithma P , Salama, Hind , Ahmed, Asra Z , Go, Ronald S , Goyal, Guarav

Mayo Clinic

British Journal of Haematology | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70939 | PMID 43014348 Get It

Summary Rosai–Dorfman disease (RDD) is a rare histiocytic neoplasm with diverse clinical behaviour and immune abnormalities with unknown clinical significance. We performed a retrospective cohort study of 162 patients with RDD from 2003 to 2025 at five international referral centres. Median age was 48 years and 64.8% were female. Multisystem disease occurred in 87 patients (53.7%), commonly involving skin/subcutaneous tissue (49.4%), lymph nodes (39.5%) and bones (34%). Molecular testing was available for 102 patients; 40 (39.2%) were mitogen‐activated protein kinase/rat sarcoma virus oncogene homolog signaling pathway (MAPK/RAS)‐altered, commonly with kirsten rat sarcoma viral oncogene homolog ( KRAS ) or mitogen‐activated protein kinase 1 ( MAP2K/MEK ) alterations. MAPK/RAS alterations were associated with multisystem disease ( p = 0.0034). Autoimmune disease (AID) was documented in 29 patients (17.9%), usually preceding RDD, and 45/95 patients (47.4%) with available autoantibody status had at least one positive autoantibody. Among 153 patients with response data, objective response occurred in 94 (61.4%). Response distribution differed by disease extent; single‐system disease was associated with more complete responses and less progression than multisystem disease. At a median follow‐up of 2.49 years, eight deaths occurred; 5‐year overall survival was 93.4%. AID and autoantibody positivity were not associated with response or overall survival. These findings support disease extent and molecular status as clinically relevant dimensions of RDD assessment, while autoimmune and serological abnormalities should be interpreted in clinical context.
Non–Prostate Cancer‐Related Factors That Influence Serum Prostate‐Specific Antigen: A Narrative Review of 45 Non‐Malignant PSA Modifiers
Stephan, Carsten , Jung, Klaus , Sutcliffe, Siobhan , Filella, Xavier , Phillips, Michael B. , Wolinsky, Howard , Ginsburg, Kevin , Keller, David K.

Mayo Clinic

The Prostate | November 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/pros.70272 | PMID 43002634 Get It

ABSTRACT Background To consolidate into a single review more than forty non‐cancer‐related factors that have been found to elevate or reduce prostate‐specific antigen (PSA) levels in the peer‐reviewed literature, emphasizing their contribution to false‐positive and false‐negative clinical interpretations. Materials and Methods A narrative literature review was conducted using PubMed, focusing on human studies describing benign physiologic, infectious, inflammatory, iatrogenic, hormonal, pharmacologic, and laboratory‐related factors that influence PSA values. The review emphasizes contemporary studies but incorporates earlier foundational literature where relevant. Results Forty‐five non‐cancer‐related factors were identified that influence PSA values through biologic, mechanical, pharmacologic, or analytic mechanisms. Thirty factors were associated with transient or persistent PSA elevation, whereas fifteen were associated with PSA reduction. Some factors varied substantially in the strength, magnitude, and consistency of reported PSA effects across studies. PSA elevations were reported in association with prostatic inflammation or infection, urinary retention, ejaculation, non‐instrumental prostatic physical stimulation, urologic instrumentation, and systemic inflammatory conditions. PSA reductions were observed with medications including 5‐alpha‐reductase inhibitors, nonsteroidal anti‐inflammatory drugs, statins, thiazide diuretics, metformin, and certain lifestyle factors. Inter‐assay and inter‐laboratory variability alone has been reported to result in PSA differences exceeding 20%. Tables summarizing the approximate magnitude and duration of PSA change for each modifier were developed, along with a patient questionnaire intended to support, not replace, clinician judgment. Conclusion PSA interpretation must incorporate awareness of more than forty influencers that can alter PSA independent of any malignancy. Accounting for these PSA level‐altering variables can improve PSA test result specificity and enhance confidence in prostate cancer risk assessment. Use of a structured patient questionnaire, a thorough consideration of benign factors that can alter PSA, repeat testing when transient factors are present, and consistent blood assay methodology can reduce unnecessary imaging, unneeded biopsies, and missed malignancies.
Drawing the Sacred: Visualizing Where Hope Lives in Hispanic Adolescent and Young Adult Cancer Survivorship
Bennett, Claire , Galchutt, Paul , Hendricks‐Ferguson, Verna L.

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21565333261504199 | PMID 42993590 Get It

Purpose: Spirituality can shape coping and meaning-making for adolescents and young adults (AYAs) with cancer, but its expression is culturally situated and may not be fully captured through interviews alone. This study examined how Hispanic AYA cancer survivors represented spirituality and hope through participant-generated drawings. Methods: This descriptive, arts-based qualitative inquiry was nested within a phenomenology-informed parent study. Ten Hispanic AYA cancer survivors completed semistructured interviews with a prospectively embedded electronic drawing activity. A board-certified art therapist conducted inductive visual thematic analysis of drawings alongside participants’ explanations; candidate themes were reviewed through team discussion and compared with previously published narrative themes. Results: Participants were 22–36 years old; seven were female and three were male, eight participants preferred to use the Spanish language, and two preferred to use the English language. Visual themes were Reliable Companionship, Religious Beliefs, and Safe Place and Containment. Participant-generated titles, explicit words and symbols, and verbal explanations anchored their interpretation. The visual dataset emphasized supportive spirituality and hope, although negative or ambiguous illness imagery also appeared. Conclusion: Participant-generated drawings offered an additional, participant-led way to examine spirituality, relationships, and place in this Hispanic AYA survivor sample. Visual methods may complement interviews when interpretation remains grounded in participants’ own meanings and culturally sensitive questioning.
Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors
Ghusn, Wissam , Abi-Aad, Sasha-Jane , Hurtado, Maria Daniela

Mayo Clinic

Journal of Clinical Medicine | October 16, 2026 | Volume: 15 | Issue: 20 | Pages: 8027

10.3390/jcm15208027 | PMID 42941539 Get It

To compare the 1-year risk of biliary/pancreatic adverse events among patients with obesity and type 2 diabetes treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4i), and to directly compare tirzepatide with semaglutide. Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Adults with obesity and type 2 diabetes without prior biliary or pancreatic disease were included. Two prespecified comparisons were performed: GLP-1RA (semaglutide or tirzepatide) versus DPP-4i, and tirzepatide versus semaglutide. The primary outcome was incident cholelithiasis at 1 year. Secondary outcomes included cholecystitis, cholangitis, acute pancreatitis, and cholecystectomy. Hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: After matching, 281,283 patients were included in each GLP-1RA and DPP-4i cohort, and 242,876 patients in each tirzepatide and semaglutide cohort. Compared with DPP-4i, GLP-1RA therapy was associated with lower risks of cholelithiasis (1.02% vs. 1.16%; HR 0.92, 95%CI 0.87–0.96), cholecystitis (HR 0.88, 95%CI 0.79–0.98), cholangitis (HR 0.46, 95%CI 0.36–0.58), acute pancreatitis (HR 0.68, 95%CI 0.61–0.76), and cholecystectomy (HR 0.51, 95%CI 0.38–0.69). In the head-to-head comparison, semaglutide was associated with higher risks of cholelithiasis (HR 1.11, 95%CI 1.05–1.18) and cholecystitis (HR 1.22, 95%CI 1.10–1.37) compared with tirzepatide, while risks of pancreatitis, cholangitis, and cholecystectomy did not differ significantly. Conclusions: In this large real-world study, GLP-1RA therapy was associated with lower risks of biliary and pancreatic events compared with DPP-4i. Tirzepatide demonstrated a modestly more favorable biliary safety profile than semaglutide, supporting the overall hepatobiliary safety of contemporary GLP-1-based therapies.
The Congenital Heart Surgeons’ Society Center for Research and Quality 2025 Annual Report
Jacobs, Jeffery P , DeCampli, William M , Honjo, Osami , Alsoufi, Bahaaldin , Jegatheeswaran, Anusha , Louis, James D. St. , Lambert, Linda M , Manlhiot, Cedric , Kumar, S Ram , Kirklin, James K. , Austin, Erle H , Overman, David M , Dearani, Joseph A. , Romano, Jennifer C , Blackstone, Eugene H.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21501351261477040 | PMID 42876309 Get It

The Congenital Heart Surgeons’ Society (CHSS) is viewed by many as one of the most prestigious professional societies dedicated to pediatric and congenital cardiac surgery. The CHSS Center for Research and Quality (CRQ) Fall 2025 Work Weekend was held in Chicago on Saturday, October 25, 2025. The purpose of this article is to summarize the proceedings of the CHSS CRQ Fall 2025 Work Weekend and to provide a 2025 Annual Report of the CHSS CRQ. At the CHSS CRQ Fall 2025 Work Weekend, multiple topics were discussed related to ongoing CHSS research and quality initiatives. The CHSS CRQ is evolving to keep pace with the rapid evolution of medical informatics and the ever-evolving regulatory issues of clinical research. This 2025 Annual Report of the CHSS CRQ summarizes some of the ongoing initiatives at CHSS CRQ designed to assure that the CHSS CRQ continues to lead innovative and collaborative clinical research to improve pediatric and congenital cardiac care.
Affective symptoms in focal epilepsy: A scoping review of localization and lateralizing findings
Sanchez-Boluarte, Sofia S , Acton, Emily K , Guevara-Lazo, S , Carrazana, Enrique , Freund, Brin E , Nascimento, Fábio A , Beniczky, Sándor , Tatum, William O

Mayo Clinic

Epileptic Disorders | October 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epd2.70438 | PMID 42873623 Get It

Abstract Emotional experiences during focal seizures are often misinterpreted as psychiatric disorders. We aimed to evaluate symptoms involving affective symptoms at seizure onset. We aimed to identify the most prevalent affective symptoms at seizure onset and characterize their localizing and lateralizing value. We performed a scoping review based on Preferred Reporting Items for Systematic reviews and Meta‐Analyses–extension for Scoping Reviews guidelines. A systematic search identified records from 4 databases: PubMed, Embase, CINAHL (via EBSCOhost), and Web of Science. Two reviewers independently screened titles/abstracts and full texts; discrepancies were resolved by consensus. This review focused on patients with focal seizures, as affective symptoms may occur in generalized epilepsies. The affective symptoms: fear, anxiety, panic, sadness, mystic, ecstatic, sexual, and mirth were identified, and semiology was evaluated in accordance with ILAE guidelines. Symptom onset, frequency, brain localization, and video‐EEG monitoring technique were evaluated to assess localization and lateralization of regional networks. Scalp EEG, invasive EEG recordings, and electrical stimulation were analyzed. A total of 1276 documents were identified, with 98 studies included for review. Fear was the most frequently reported ictal emotion, identified in 274 patients (66%), predominantly in temporal lobe epilepsy. Sadness and sexual, ecstatic symptoms were also consistently associated with temporal networks. Mirth was more frequently reported with frontal onset seizures. Evidence, primarily from Class IV studies, reported right hemispheric predominance for ecstasy, mystic, and sexual symptoms at seizure onset. Ictal affective symptoms at seizure onset yield localizing information. The limbic system, especially the temporal lobe, followed by the frontal lobe, was the most common site of origin. Fear was the most common spontaneous and electrically elicited symptom, followed by anxiety. While bi‐hemispheric lateralization occurred, right lateralization predominated. Recognizing paroxysmal affective symptoms as ictal phenomena may reduce misdiagnosis and aid presurgical evaluation in drug‐resistant focal epilepsy.
Return‐to‐Sport Assessment After Medial Patellofemoral Ligament Reconstruction Shows Substantial Variability in Objective Criteria
Kang, Louis S , Ward, Gavin H , Hevesi, Mario , Saris, Daniël B.F. , Camp, Christopher L. , Krych, Aaron J , Tagliero, Adam

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | October 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ars2.70110 | PMID 42876992 Get It

Purpose To evaluate objective return‐to‐sport (RTS) outcomes and limb symmetry index (LSI) data after primary medial patellofemoral ligament reconstruction (MPFLR) in patients with patellar instability. Methods A systematic search of Scopus, PubMed, CINAHL, and Embase (2000‐2024) identified studies reporting RTS outcomes and LSI‐based performance testing in patients undergoing primary MPFLR. Clinical and observational studies reporting objective metrics such as isokinetic strength and hop testing were included. Results Six studies including 243 patients (64% women, mean age 19.4 years) undergoing primary MPFLR were included. Several studies included patients undergoing concomitant bone procedures (41%), such as tibial tubercle osteotomy or trochleoplasty. Objective RTS testing commonly included isokinetic strength (4 studies), hop testing (3 studies), and Y‐Balance testing (2 studies). Follow‐up testing ranged from 6 to 8 months postoperatively. Reported LSI values ranged from 83% to 94% for isokinetic flexion, 70% to 96% for isokinetic extension, 85% to 93% for single hop, and 90% to 97% for triple hop. Time to RTS ranged from 6.1 to 8.1 months across studies, with RTS rates from 85% to 100%. However, only 14% to 40% of patients met all study‐specific RTS criteria when reported. Testing protocols and thresholds varied across studies, contributing to heterogeneity in outcomes. Conclusions Few studies reporting RTS outcomes after MPFLR incorporate LSI measures as part of RTS assessment, and only a minority define explicit RTS criteria based on objective testing. Among studies that reported LSI, quadriceps strength frequently remained below 90% LSI at the time of RTS. Despite high reported RTS rates, substantial variability exists in RTS assessment after MPFLR. Level of Evidence Level IV, systematic review of Level III to IV studies.
Association Between Early Postoperative Limb Symmetry Index Scores and 2-Year Patient-Reported Outcomes After Quadriceps Tendon Autograft ACL Reconstruction
Kang, Louis S , Ina, Jason G , Johnson, Andrew , Duchman, Kyle R , Hevesi, Mario , Camp, Christopher L. , Krych, Aaron J , Tagliero, Adam

Mayo Clinic

The American Journal of Sports Medicine | October 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/03635465261490238 | PMID 42852663 Get It

Background: The limb symmetry index (LSI) is a measure comparing strength and functional movement between the surgical and nonsurgical limbs, used after anterior cruciate ligament reconstruction (ACLR) to guide rehabilitation and assess return-to-sport readiness. With increasing use of the quadriceps tendon autograft (QT-ACLR), limited data exist on whether the LSI score correlates with patient-reported outcome measures (PROMs). Hypothesis/Purpose: To evaluate the predictive value of postoperative strength and functional LSI tests at 3, 6, and 9 months for short-term PROMs, determine Patient Acceptable Symptom State (PASS) thresholds, and assess differences based on PASS achievement. It was hypothesized that quadriceps strength LSI score would more strongly predict 2-year PROMs than hamstring strength LSI score, and that higher 9-month isokinetic quadriceps LSI scores would be associated with higher International Knee Documentation Committee (IKDC) and Lysholm scores. Study Design: Case series; Level of evidence, 4. Methods: Patients undergoing primary QT-ACLR from 2021 to 2024 with LSI testing during rehabilitation (isometric and isokinetic lower extremity strength, Y-Balance, hop testing) and no revision or additional knee surgery were included. The LSI score was assessed at 3, 6, and 9 months, and PROMs, including Lysholm and IKDC scores, were collected at a mean follow-up of 2.0 ± 0.7 years. Multivariable linear regression was used to evaluate associations between LSI measures and PROMs after adjusting for age, sex, and body mass index (BMI). Receiver operating characteristic analysis was used to determine PASS thresholds. Results: A total of 100 knees in 100 patients (mean age, 25.3 ± 11.2 years; BMI, 25.9 ± 6.5 kg/m 2 ; 52% male) were included. Quadriceps and hamstring strength and functional performance progressively improved from 3 to 9 months, with the LSI score reaching 77% to 81% for quadriceps strength and 98% to 100% for hamstring strength by 9 months postoperatively. At a mean follow-up of 2.0 ± 0.7 years, the mean satisfaction score was 8.4 of 10, the Lysholm score was 90.7, and the IKDC score was 77.8. Linear regression, adjusted for age, sex, and BMI, demonstrated that 3-month isometric quadriceps LSI score had a strong effect on IKDC score, explaining substantial variance (β = 3.9; adjusted R 2 [Adj R 2 ] = 0.36; P < .03); 6-month isokinetic quadriceps and hamstrings showed moderate but significant effects (β = 2.9-3.7; Adj R 2 = 0.13-0.17; P < .05) on IKDC score; and 9-month fast quadriceps had a strong effect explaining substantial variance in Lysholm and IKDC scores (β = 3.9-4.7; Adj R 2 = 0.34-0.35; P ≤ .003). Lysholm and IKDC scores correlated with satisfaction and accurately discriminated PASS thresholds (area under the curve, 0.927-0.937; P < .001). Patients achieving the IKDC PASS demonstrated higher LSI scores across time points and all PROMs. Conclusion: After QT-ACLR, strength-associated LSIs were independently associated with PROMs at a mean 2-year follow-up, after adjusting for age, sex, and BMI. Early isometric quadriceps strength at 3 months predicted higher 2-year IKDC scores, with PASS achievers generally attaining a 60% to 70% LSI score by 3 months. Isokinetic quadriceps strength at 9 months predicted both IKDC and Lysholm scores. These findings highlight the importance of early quadriceps strength recovery and the value of LSI measures in predicting PROMs and informing early rehabilitation.
An Evidence-Based Approach to Zenker's Diverticulum: From Diagnosis to Tailored Treatment
Kim, Marina

Mayo Clinic

American Journal of Gastroenterology | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004228 | PMID 42847187 Get It